1-20 of 222
Authors: David P. Nicolau
Save search
Sort by
Journal Article

Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model Open Access

PDF
Andrew J Fratoni and others
Journal of Antimicrobial Chemotherapy, dkaf100, https://doi.org/10.1093/jac/dkaf100
Published: 27 March 2025
Journal Article

P-1216. Comparison of the in vivo Efficacy and Resistance Development Potential between Cefiderocol (FDC) and Ceftolozane/tazobactam (C/T) Human Simulated Exposures against Pseudomonas aeruginosa in 72 Hour Murine Thigh Infection Model Open Access

PDF
Aliaa Fouad and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1398, https://doi.org/10.1093/ofid/ofae631.1398
Published: 29 January 2025
Journal Article

P-1226. Dose Optimization of β-lactams against Carbapenem-Resistant Pseudomonas from Turkiye Defined as Susceptible to Ceftazidime, Cefepime or Piperacillin/Tazobactam Open Access

PDF
Ecem Buyukyanbolu and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1408, https://doi.org/10.1093/ofid/ofae631.1408
Published: 29 January 2025
Journal Article

P-1653. Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) across Outpatient and Urgent Care Visits Open Access

PDF
Tomefa E Asempa and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1819, https://doi.org/10.1093/ofid/ofae631.1819
Published: 29 January 2025
Journal Article

P-1221. Benchmark Efficacy for Humanized Cefiderocol Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures Against Gram Negative Isolates in Standardized Murine Lung Infection Model Open Access

PDF
Andrew J Fratoni and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1403, https://doi.org/10.1093/ofid/ofae631.1403
Published: 29 January 2025
Journal Article

P-1220. Humanizing Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures of Cefiderocol in Standardized Murine Lung Infection Model Open Access

PDF
Andrew J Fratoni and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1402, https://doi.org/10.1093/ofid/ofae631.1402
Published: 29 January 2025
Journal Article

511. Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023 – 2024) Open Access

PDF
Ecem Buyukyanbolu and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.163, https://doi.org/10.1093/ofid/ofae631.163
Published: 29 January 2025
Journal Article

207. Ex vivo Assessment of Cefepime (FEP) Clearance during Continuous Renal Replacement Therapy (CRRT) and Clinical Validation of Optimized Dosing Regimens Open Access

PDF
Christina Konig and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.065, https://doi.org/10.1093/ofid/ofae631.065
Published: 29 January 2025
Journal Article

P-1219. Benchmarks for Humanized Meropenem Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures Against Klebsiella pneumoniae in Standardized Murine Lung Infection Model Open Access

PDF
Andrew J Fratoni and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1401, https://doi.org/10.1093/ofid/ofae631.1401
Published: 29 January 2025
Journal Article

P-1217. Validation of Cefiderocol (FDC) Package Insert Dosing Recommendation for Patients receiving Continuous Renal Replacement Therapy (CRRT): A Prospective Multi-Center Pharmacokinetic Study Open Access

PDF
Aliaa Fouad and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1399, https://doi.org/10.1093/ofid/ofae631.1399
Published: 29 January 2025
Journal Article

P-1227. Population Pharmacokinetics (PK) of Cefiderocol (FDC) during Acute Pulmonary Exacerbations (APE) in Adult Persons with Cystic Fibrosis (CF) Open Access

PDF
Christina Konig and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1409, https://doi.org/10.1093/ofid/ofae631.1409
Published: 29 January 2025
Journal Article

P-1067. In Vitro Potency of Ceftibuten-Avibactam (CTB-AVI) and Comparators against Extended-Spectrum Beta-Lactamase (ESBL)-like Enterobacterales from Outpatient Centers and Nursing Homes in the United States Open Access

PDF
Aliaa Fouad and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1255, https://doi.org/10.1093/ofid/ofae631.1255
Published: 29 January 2025
Journal Article

P-1341. Differential Frequency of Persister cells in Clinically Derived Pseudomonas aeruginosa Isolates after Exposure to Cefiderocol (FDC) or Ceftolozane/tazobactam (C/T) Open Access

PDF
Aliaa Fouad and others
Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.1518, https://doi.org/10.1093/ofid/ofae631.1518
Published: 29 January 2025
Journal Article

Pharmacokinetic/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: establishing in vivo efficacy targets in the epithelial lining fluid Open Access

PDF
Yasmeen Abouelhassan and others
JAC-Antimicrobial Resistance, Volume 6, Issue 6, December 2024, dlae203, https://doi.org/10.1093/jacamr/dlae203
Published: 20 December 2024
Journal Article

Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model Open Access

PDF
Andrew J Fratoni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 2, February 2025, Pages 478–484, https://doi.org/10.1093/jac/dkae432
Published: 05 December 2024
Journal Article

Establishment of a diverse pheno-genotypic challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa suitable for use in the murine pneumonia model Open Access

PDF
Andrew J Fratoni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 1, January 2025, Pages 154–161, https://doi.org/10.1093/jac/dkae388
Published: 30 October 2024
Journal Article

Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam Get access

PDF
Aliaa Fouad and others
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 12, December 2024, Pages 3236–3242, https://doi.org/10.1093/jac/dkae346
Published: 24 October 2024
Journal Article

Validation of Cefiderocol Package Insert Dosing Recommendation for Patients Receiving Continuous Renal Replacement Therapy: A Prospective Multicenter Pharmacokinetic Study Open Access

PDF
Aliaa Fouad and others
Open Forum Infectious Diseases, Volume 11, Issue 10, October 2024, ofae451, https://doi.org/10.1093/ofid/ofae451
Published: 21 October 2024
Journal Article

Quantitative performance of humanized serum and epithelial lining fluid exposures of tigecycline and levofloxacin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model Open Access

PDF
Andrew J Fratoni and others
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 12, December 2024, Pages 3142–3149, https://doi.org/10.1093/jac/dkae333
Published: 18 October 2024
Journal Article

Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations Get access

PDF
Yasmeen Abouelhassan and others
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 9, September 2024, Pages 2227–2236, https://doi.org/10.1093/jac/dkae218
Published: 20 July 2024